Spencer Berthelsen Biography and Net Worth

Director of Ionis Pharmaceuticals

Dr. Berthelsen has served as a director of Ionis since May 2002. Since 1980, he has practiced Internal Medicine with the Kelsey Seybold Clinic, a 400-physician medical group based in the Texas Medical Center in Houston. Dr. Berthelsen has served in various senior leadership positions at Kelsey Seybold, including chairman of the Department of Internal Medicine, medical director and managing director. He served as chairman of their Board of Directors from October 2001 through April 2016. He has served as a clinical professor of Medicine at Baylor College of Medicine and the University of Texas Health Science Center of Houston. Dr. Berthelsen served on the board of the Texas Academy of Internal Medicine in the past and the Caremark National Pharmacy and Therapeutics Committee from 1999 through 2005.

What is Spencer R. Berthelsen's net worth?: The estimated net worth of Spencer R. Berthelsen is at least $3.94 million as of June 23rd, 2021. Dr. Berthelsen owns 115,983 shares of Ionis Pharmaceuticals stock worth more than $3,944,582 as of November 23rd. This net worth approximation does not reflect any other investments that Dr. Berthelsen may own. Learn More about Spencer R. Berthelsen's net worth.
How do I contact Spencer R. Berthelsen?: The corporate mailing address for Dr. Berthelsen and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Spencer R. Berthelsen's contact information.
Has Spencer R. Berthelsen been buying or selling shares of Ionis Pharmaceuticals?: Spencer R. Berthelsen has not been actively trading shares of Ionis Pharmaceuticals in the last ninety days. Most recently, Spencer R. Berthelsen sold 15,000 shares of the business's stock in a transaction on Wednesday, June 23rd. The shares were sold at an average price of $37.74, for a transaction totalling $566,100.00. Following the completion of the sale, the director now directly owns 115,983 shares of the company's stock, valued at $4,377,198.42. Learn More on Spencer R. Berthelsen's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, insiders at the sold shares 25 times. They sold a total of 270,830 shares worth more than $13,480,539.63. The most recent insider tranaction occured on November, 12th when EVP Eric Swayze sold 1,194 shares worth more than $45,276.48. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 11/12/2024.

Spencer R. Berthelsen Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/23/2021	Sell	15,000	$37.74	$566,100.00	115,983
6/23/2020	Sell	15,000	$58.76	$881,400.00	111,983
6/24/2019	Sell	15,000	$63.67	$955,050.00	99,404
6/25/2018	Sell	15,000	$42.30	$634,500.00	97,127

Spencer R. Berthelsen Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $34.01

$33.92

$34.76

50 Day Range

MA: $38.87

$33.73

$42.76

2 Week Range

Now: $34.01

$33.33

$54.44

Volume

2,422,690 shs

Average Volume

1,282,095 shs

Market Capitalization

$5.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.